HIT to LEAD to Candidate development of a Transcription Repressor Inhibitory Compound (TRIC), which switches off bacterial resistance to a broad band antibiotic
Beschreibung
A new and highly innovative treatment will be realized by a novel and patentable orally available small molecule combinatorial drug candidate for the treatment of antibiotic resistance in multi-resistant, pathogenic bacterial strains.
Eckdaten
Projektleitung
Projektteam
Dr. Mark Sephton, Patrik Züger
Projektpartner
BioVersys AG
Projektstatus
abgeschlossen, 11/2011 - 10/2013
Institut/Zentrum
Institut für Chemie und Biotechnologie (ICBT)
Drittmittelgeber
KTI-Projekt
Projektvolumen
1'382'297 CHF
Life Sciences und Facility Management
Einsiedlerstrasse 31
8820 Wädenswil